MedDataX Logo

Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)

NCT ID: NCT05084950

Last Updated: 2021-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2 COVID-19 Vaccines Antibody

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must live in the Principality of Monaco
* Deliver a written consent to participate to the study
* And/Or Have been infected with SARS-CoV-2
* And/Or Have been, or are about to be, vaccinated against SARS-CoV-2

Exclusion Criteria

\- None of the above
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Department of Health Affairs, Monaco

UNKNOWN

Sponsor Role collaborator

Centre Scientifique de Monaco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre National de Depistage - Espace Leo Ferre

Monaco, , Monaco

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Monaco

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eric VOIGLIO, MD, PhD

Role: CONTACT

[email protected]
+37798984850

Thomas ALTHAUS, MD, PhD

Role: CONTACT

[email protected]
+37798984850

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Eric VOIGLIO, MD, PhD

Role: primary

[email protected]
+37798984850

Thomas ALTHAUS, MD, PhD

Role: backup

[email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO_CSM_02_2021

Identifier Type: -

Identifier Source: org_study_id